Acorda Therapeutics, Inc. (ACOR) News
Filter ACOR News Items
ACOR News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest ACOR News From Around the Web
Below are the latest news stories about Acorda Therapeutics Inc that investors may wish to consider to help them evaluate ACOR as an investment opportunity.
Acorda Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual ConferenceARDSLEY, N.Y., January 04, 2022--Acorda Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference |
John Varian Joins Acorda Therapeutics Board of DirectorsARDSLEY, N.Y., January 03, 2022--John Varian joins Acorda Therapeutics Board of Directors |
Multiple Sclerosis Market to Witness Notable Growth by 2027 Covid-19 Analysis | Abbvie, Acorda TherapeuticsThis Multiple Sclerosis market report describes the factors that contribute to the sector''s development as well as market channels. When taken in order, this Multiple Sclerosis market report starts with an introduction to the commercial chain structure and then moves |
Ataxia Market Expected to Expand at a Steady 2021-2028 | Pfizer, Inc., CRISPR Therapeutics, Acorda Therapeutics, Capsida Biotherapeutics Inc."Industry analysis is a crucial step in the current competitive market space that helps identify the right target customers and accordingly provide tailored solutions for their business needs. Every aspect and unique challenges put up by the particular industry are |
Global Multiple Sclerosis Drugs Market Research Report 2021 Featuring Biogen, Novartis, Roche, Bayer HealthCare, Pfizer., Merck & Co, Sanofi, Teva Pharm, GSK and Acorda Therapeutics - ResearchAndMarkets.comDUBLIN--(BUSINESS WIRE)--The "Multiple Sclerosis Drugs Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com''s offering. The global multiple sclerosis drugs market is expected to grow from $21.27 billion in 2020 to $22.04 billion in 2021 at a compound annual growth rate (CAGR) of 3.6%. The market is expected to reach $25.95 billion in 2025 at a CAGR of 4%. Major players in the multiple sclerosis drugs market are Biogen, Novartis, Roche, B |
Worldwide Multiple Sclerosis Drugs Industry to 2027 - Featuring Abbvie, Acorda Therapeutics and Biogen Among Others - ResearchAndMarkets.comDUBLIN--(BUSINESS WIRE)--The "Global Multiple Sclerosis Drugs Market 2020-2027" report has been added to ResearchAndMarkets.com''s offering. The global multiple sclerosis drugs market will reach $29.97 billion by 2027, growing by 4.3% annually over 2020-2027 owing to the growing prevalence of multiple sclerosis (MS), the rise in funding for multiple sclerosis research, and increasing approvals of novel MS drugs. The report is based on a comprehensive research of the entire global multiple sclero |
Acorda Therapeutics, Inc. (NASDAQ:ACOR) Short Interest UpdateAcorda Therapeutics, Inc. (NASDAQ:ACOR) saw a significant increase in short interest during the month of November. As of November 15th, there was short interest totalling 587,000 shares, an increase of 34.9% from the October 31st total of 435,000 shares. Based on an average daily trading volume, of 142,400 shares, the days-to-cover ratio is presently 4.1 [] The post Acorda Therapeutics, Inc. (NASDAQ:ACOR) Short Interest Update appeared first on ETF Daily News . |
Geode Capital Management LLC Has $350,000 Stake in Acorda Therapeutics, Inc. (NASDAQ:ACOR)Geode Capital Management LLC raised its stake in Acorda Therapeutics, Inc. (NASDAQ:ACOR) by 13.4% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 73,562 shares of the biopharmaceutical companys stock after buying an additional 8,706 shares during the quarter. Geode Capital Management LLC [] |
Acorda Therapeutics Reports Third Quarter 2021 Financial Results, Additions to Leadership TeamARDSLEY, N.Y., November 09, 2021--Acorda Therapeutics Reports Third Quarter 2021 Financial Results, Additions to Leadership Team |
Acorda Therapeutics Announces Agreement to Commercialize INBRIJA® in GermanyARDSLEY, N.Y., November 09, 2021--Acorda Therapeutics Announces Agreement to Commercialize INBRIJA® in Germany |